FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 354:809-820 February 23, 2006 Number 8 Next

	Full Text PDF PDA Full Text PowerPoint Slide Set Supplementary Material Perspective by Chien, K. R. Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

ABSTRACT

Background We compared docetaxel with vinorelbine for the adjuvant treatment of early breast cancer. Women with tumors that overexpressed HER2/neu were also assigned to receive concomitant treatment with trastuzumab or no such treatment.

Methods We randomly assigned 1010 women with axillary-node–positive or high-risk node-negative cancer to receive three cycles of docetaxel or vinorelbine, followed by (in both groups) three cycles of fluorouracil, epirubicin, and cyclophosphamide. The 232 women whose tumors had an amplified HER2/neu gene were further assigned to receive or not to receive nine weekly trastuzumab infusions. The primary end point was recurrence-free survival.

Results Recurrence-free survival at three years was better with docetaxel than with vinorelbine (91 percent vs. 86 percent; hazard ratio for recurrence or death, 0.58; 95 percent confidence interval, 0.40 to 0.85; P=0.005), but overall survival did not differ between the groups (P=0.15). Within the subgroup of patients who had HER2/neu-positive cancer, those who received trastuzumab had better three-year recurrence-free survival than those who did not receive the antibody (89 percent vs. 78 percent; hazard ratio for recurrence or death, 0.42; 95 percent confidence interval, 0.21 to 0.83; P=0.01). Docetaxel was associated with more adverse effects than was vinorelbine. Trastuzumab was not associated with decreased left ventricular ejection fraction or cardiac failure.

Conclusions Adjuvant treatment with docetaxel, as compared with vinorelbine, improves recurrence-free survival in women with early breast cancer. A short course of trastuzumab administered concomitantly with docetaxel or vinorelbine is effective in women with breast cancer who have an amplified HER2/neu gene. (International Standard Randomised Controlled Trial number, ISRCTN76560285 [controlled-trials.com].)

Source Information

From the Department of Oncology, Helsinki University Central Hospital, Helsinki (H.J., P.B., T.A., T.U., A.H., M.T., A.-S.J., I.E.); the Department of Oncology, Tampere University Hospital (P.-L.K.-L., T.S.), and the Laboratory of Cancer Biology, Institute of Medical Technology, University of Tampere and Tampere University Hospital (J.I.), Tampere; the Department of Oncology, Kuopio University Hospital, Kuopio (V.K.); Satakunta Central Hospital, Pori (R.A.); Hämeenlinna Central Hospital, Hämeenlinna (R.K.); the Department of Oncology and Radiotherapy, Oulu University Hospital, Oulu (T.T.-H.); the Department of Oncology, Turku University Central Hospital, Turku (S.J.); South Karelia Central Hospital, Lappeenranta (M.F.); Kotka Central Hospital, Kotka (L.H.); Vaasa Central Hospital, Vaasa (S.I.); Kokkola Central Hospital, Kokkola (K.J.); Jyväskylä Central Hospital, Jyväskylä (M.P.); Kajaani Central Hospital, Kajaani (M.R.); Kemi Central Hospital, Kemi (J.K.-K.); and 4Pharma, Turku (M.L.) — all in Finland.

Address reprint requests to Dr. Joensuu at the Department of Oncology, Helsinki University Central Hospital, Haartmaninkatu 4, P.O.B. 180, FIN-00029 Helsinki, Finland.

Full Text of this Article

Related Letters:

Trastuzumab Treatment in Breast Cancer
Montemurro F., Valabrega G., Aglietta M., Joensuu H., Bono P., Kellokumpu-Lehtinen P.
Extract | Full Text | PDF  
N Engl J Med 2006; 354:2186, May 18, 2006. Correspondence

This article has been cited by other articles:

• Dowsett, M., Procter, M., McCaskill-Stevens, W., de Azambuja, E., Dafni, U., Rueschoff, J., Jordan, B., Dolci, S., Abramovitz, M., Stoss, O., Viale, G., Gelber, R. D., Piccart-Gebhart, M., Leyland-Jones, B. (2009). Disease-Free Survival According to Degree of HER2 Amplification for Patients Treated With Adjuvant Chemotherapy With or Without 1 Year of Trastuzumab: The HERA Trial. JCO 27: 2962-2969 [Abstract] [Full Text]  
• Goldhirsch, A., Ingle, J. N., Gelber, R. D., Coates, A. S., Thurlimann, B., Senn, H.-J., Panel members, (2009). Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2009. Ann Oncol 0: mdp322v1-mdp322 [Abstract] [Full Text]  
• Halyard, M. Y., Pisansky, T. M., Dueck, A. C., Suman, V., Pierce, L., Solin, L., Marks, L., Davidson, N., Martino, S., Kaufman, P., Kutteh, L., Dakhil, S. R., Perez, E. A. (2009). Radiotherapy and Adjuvant Trastuzumab in Operable Breast Cancer: Tolerability and Adverse Event Data From the NCCTG Phase III Trial N9831. JCO 27: 2638-2644 [Abstract] [Full Text]  
• Kataja, V., Castiglione, M., On behalf of the ESMO Guidelines Working Group, (2009). Primary breast cancer: ESMO Clinical Recommendations for diagnosis, treatment and follow-up. Ann Oncol 20: iv10-iv14 [Full Text]  
• Sparano, J. A., Moulder, S., Kazi, A., Coppola, D., Negassa, A., Vahdat, L., Li, T., Pellegrino, C., Fineberg, S., Munster, P., Malafa, M., Lee, D., Hoschander, S., Hopkins, U., Hershman, D., Wright, J. J., Kleer, C., Merajver, S., Sebti, S. M. (2009). Phase II Trial of Tipifarnib plus Neoadjuvant Doxorubicin-Cyclophosphamide in Patients with Clinical Stage IIB-IIIC Breast Cancer. Clin. Cancer Res. 15: 2942-2948 [Abstract] [Full Text]  
• Gong, Y., Sweet, W., Duh, Y.-J., Greenfield, L., Fang, Y., Zhao, J., Tarco, E., Symmans, W. F., Isola, J., Sneige, N. (2009). Chromogenic In Situ Hybridization Is a Reliable Method for Detecting HER2 Gene Status in Breast Cancer: A Multicenter Study Using Conventional Scoring Criteria and the New ASCO/CAP Recommendations. Am J Clin Pathol 131: 490-497 [Abstract] [Full Text]  
• Ross, J. S., Slodkowska, E. A., Symmans, W. F., Pusztai, L., Ravdin, P. M., Hortobagyi, G. N. (2009). The HER-2 Receptor and Breast Cancer: Ten Years of Targeted Anti-HER-2 Therapy and Personalized Medicine. The Oncologist 14: 320-368 [Abstract] [Full Text]  
• Ignatiadis, M., Desmedt, C., Sotiriou, C., de Azambuja, E., Piccart, M. (2009). HER-2 as a Target for Breast Cancer Therapy. Clin. Cancer Res. 15: 1848-1852 [Full Text]  
• Bono, P., Kellokumpu-Lehtinen, P.-L., Alanko, T., Kokko, R., Asola, R., Turpeenniemi-Hujanen, T., Jyrkkio, S., Kataja, V., Leinonen, M., Joensuu, H. (2009). Docetaxel 100 versus 80 mg/m2 as adjuvant treatments of early breast cancer: an exploratory analysis of a randomised trial. Ann Oncol 20: 595-596 [Full Text]  
• Sinclair, S., Zimmer, A. S., Swain, S. M. (2009). HER-2 Targeting Agents and Antiangiogenic Therapy: Evolution of Adjuvant Therapy in Breast Cancer. Am Soc Clin Oncol Ed Book 2009: 3-10 [Abstract] [Full Text]  
• Cortes, J., Di Cosimo, S., Climent, M. A., Cortes-Funes, H., Lluch, A., Gascon, P., Mayordomo, J. I., Gil, M., Benavides, M., Cirera, L., Ojeda, B., Rodriguez, C. A., Trigo, J. M., Vazquez, J., Regueiro, P., Dorado, J. F., Baselga, J., on behalf of the Spanish Breast Cancer Cooperative, (2009). Nonpegylated Liposomal Doxorubicin (TLC-D99), Paclitaxel, and Trastuzumab in HER-2-Overexpressing Breast Cancer: A Multicenter Phase I/II Study. Clin. Cancer Res. 15: 307-314 [Abstract] [Full Text]  
• Morris, P. G., McArthur, H. L., Dang, C. T., Hudis, C. A. (2009). Selection of Appropriate Patients for Anthracycline Therapy. Am Soc Clin Oncol Ed Book 2009: 11-18 [Abstract] [Full Text]  
• Martin, M., Esteva, F. J., Alba, E., Khandheria, B., Perez-Isla, L., Garcia-Saenz, J. A., Marquez, A., Sengupta, P., Zamorano, J. (2009). Minimizing Cardiotoxicity While Optimizing Treatment Efficacy with Trastuzumab: Review and Expert Recommendations. The Oncologist 14: 1-11 [Abstract] [Full Text]  
• Chia, S., Norris, B., Speers, C., Cheang, M., Gilks, B., Gown, A. M., Huntsman, D., Olivotto, I. A., Nielsen, T. O., Gelmon, K. (2008). Human Epidermal Growth Factor Receptor 2 Overexpression As a Prognostic Factor in a Large Tissue Microarray Series of Node-Negative Breast Cancers. JCO 26: 5697-5704 [Abstract] [Full Text]  
• Vanden Bempt, I., Van Loo, P., Drijkoningen, M., Neven, P., Smeets, A., Christiaens, M.-R., Paridaens, R., De Wolf-Peeters, C. (2008). Polysomy 17 in Breast Cancer: Clinicopathologic Significance and Impact on HER-2 Testing. JCO 26: 4869-4874 [Abstract] [Full Text]  
• Arteaga, C. L., O'Neill, A., Moulder, S. L., Pins, M., Sparano, J. A., Sledge, G. W., Davidson, N. E. (2008). A Phase I-II Study of Combined Blockade of the ErbB Receptor Network with Trastuzumab and Gefitinib in Patients with HER2 (ErbB2)-Overexpressing Metastatic Breast Cancer. Clin. Cancer Res. 14: 6277-6283 [Abstract] [Full Text]  
• Srinivasan, S., Parsa, V., Liu, C. Y, Fontana, J. A (2008). Trastuzumab-Induced Hepatotoxicity. The Annals of Pharmacotherapy 42: 1497-1501 [Abstract] [Full Text]  
• Schmidt, M., Hasenclever, D., Schaeffer, M., Boehm, D., Cotarelo, C., Steiner, E., Lebrecht, A., Siggelkow, W., Weikel, W., Schiffer-Petry, I., Gebhard, S., Pilch, H., Gehrmann, M., Lehr, H.-A., Koelbl, H., Hengstler, J. G., Schuler, M. (2008). Prognostic Effect of Epithelial Cell Adhesion Molecule Overexpression in Untreated Node-Negative Breast Cancer. Clin. Cancer Res. 14: 5849-5855 [Abstract] [Full Text]  
• Goldstein, L. J., Gray, R., Badve, S., Childs, B. H., Yoshizawa, C., Rowley, S., Shak, S., Baehner, F. L., Ravdin, P. M., Davidson, N. E., Sledge, G. W. Jr, Perez, E. A., Shulman, L. N., Martino, S., Sparano, J. A. (2008). Prognostic Utility of the 21-Gene Assay in Hormone Receptor-Positive Operable Breast Cancer Compared With Classical Clinicopathologic Features. JCO 26: 4063-4071 [Abstract] [Full Text]  
• Rayson, D., Richel, D., Chia, S., Jackisch, C., van der Vegt, S., Suter, T. (2008). Anthracycline-trastuzumab regimens for HER2/neu-overexpressing breast cancer: current experience and future strategies. Ann Oncol 19: 1530-1539 [Abstract] [Full Text]  
• Anderson, J. R., Cain, K. C., Gelber, R. D. (2008). Analysis of Survival by Tumor Response and Other Comparisons of Time-to-Event by Outcome Variables. JCO 26: 3913-3915 [Full Text]  
• Nunes, C B, Rocha, R M, Reis-Filho, J S, Lambros, M B, Rocha, G F S, Sanches, F S F, Oliveira, F N, Gobbi, H (2008). Comparative analysis of six different antibodies against Her2 including the novel rabbit monoclonal antibody (SP3) and chromogenic in situ hybridisation in breast carcinomas. J. Clin. Pathol. 61: 934-938 [Abstract] [Full Text]  
• Holmes, J. P., Benavides, L. C., Gates, J. D., Carmichael, M. G., Hueman, M. T., Mittendorf, E. A., Murray, J. L., Amin, A., Craig, D., von Hofe, E., Ponniah, S., Peoples, G. E. (2008). Results of the First Phase I Clinical Trial of the Novel Ii-Key Hybrid Preventive HER-2/neu Peptide (AE37) Vaccine. JCO 26: 3426-3433 [Abstract] [Full Text]  
• Walker, R A, Bartlett, J M S, Dowsett, M, Ellis, I O, Hanby, A M, Jasani, B, Miller, K, Pinder, S E (2008). HER2 testing in the UK: further update to recommendations. J. Clin. Pathol. 61: 818-824 [Abstract] [Full Text]  
• MacKenzie, R., Chapman, S., Salkeld, G., Holding, S. (2008). Media influence on Herceptin subsidization in Australia: application of the rule of rescue?. JRSM 101: 305-312 [Abstract] [Full Text]  
• Kulkarni, S., Hicks, D. G. (2008). HER2-Positive Early Breast Cancer and Trastuzumab: A Surgeon's Perspective. Ann. Surg. Oncol. 15: 1677-1688 [Abstract] [Full Text]  
• Untch, M., Gelber, R. D., Jackisch, C., Procter, M., Baselga, J., Bell, R., Cameron, D., Bari, M., Smith, I., Leyland-Jones, B., de Azambuja, E., Wermuth, P., Khasanov, R., Feng-yi, F., Constantin, C., Mayordomo, J. I., Su, C.-H., Yu, S.-Y., Lluch, A., Senkus-Konefka, E., Price, C., Haslbauer, F., Sahui, T. S., Srimuninnimit, V., Colleoni, M., Coates, A. S., Piccart-Gebhart, M. J., Goldhirsch, A., for the HERA Study Team, (2008). Estimating the magnitude of trastuzumab effects within patient subgroups in the HERA trial. Ann Oncol 19: 1090-1096 [Abstract] [Full Text]  
• Belkacemi, Y., Gligorov, J., Ozsahin, M., Marsiglia, H., De Lafontan, B., Laharie-Mineur, H., Aimard, L., Antoine, E.-C., Cutuli, B., Namer, M., Azria, D. (2008). Concurrent trastuzumab with adjuvant radiotherapy in HER2-positive breast cancer patients: acute toxicity analyses from the French multicentric study. Ann Oncol 19: 1110-1116 [Abstract] [Full Text]  
• Walker, R A (2008). Immunohistochemical markers as predictive tools for breast cancer. J. Clin. Pathol. 61: 689-696 [Abstract] [Full Text]  
• Dahabreh, I. J., Linardou, H., Siannis, F., Fountzilas, G., Murray, S. (2008). Trastuzumab in the Adjuvant Treatment of Early-Stage Breast Cancer: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. The Oncologist 13: 620-630 [Abstract] [Full Text]  
• Ignatiadis, M., Kallergi, G., Ntoulia, M., Perraki, M., Apostolaki, S., Kafousi, M., Chlouverakis, G., Stathopoulos, E., Lianidou, E., Georgoulias, V., Mavroudis, D. (2008). Prognostic Value of the Molecular Detection of Circulating Tumor Cells Using a Multimarker Reverse Transcription-PCR Assay for Cytokeratin 19, Mammaglobin A, and HER2 in Early Breast Cancer. Clin. Cancer Res. 14: 2593-2600 [Abstract] [Full Text]  
• Dang, C., Fornier, M., Sugarman, S., Troso-Sandoval, T., Lake, D., D'Andrea, G., Seidman, A., Sklarin, N., Dickler, M., Currie, V., Gilewski, T., Moynahan, M. E., Drullinsky, P., Robson, M., Wasserheit-Leiblich, C., Mills, N., Steingart, R., Panageas, K., Norton, L., Hudis, C. (2008). The Safety of Dose-Dense Doxorubicin and Cyclophosphamide Followed by Paclitaxel With Trastuzumab in HER-2/neu Overexpressed/Amplified Breast Cancer. JCO 26: 1216-1222 [Abstract] [Full Text]  
• Lidgren, M., Jonsson, B., Rehnberg, C., Willking, N., Bergh, J. (2008). Cost-effectiveness of HER2 testing and 1-year adjuvant trastuzumab therapy for early breast cancer. Ann Oncol 19: 487-495 [Abstract] [Full Text]  
• Konsti, J, Lundin, J, Jumppanen, M, Lundin, M, Viitanen, A, Isola, J (2008). A public-domain image processing tool for automated quantification of fluorescence in situ hybridisation signals. J. Clin. Pathol. 61: 278-282 [Abstract] [Full Text]  
• Tran, L.-P. P., Grabinski, J. L. (2008). Chemotherapy for Early-Stage Breast Cancer: A Paradigm in Flux. Journal of Pharmacy Practice 21: 46-56 [Abstract]  
• Azambuja, E., Durbecq, V., Rosa, D. D., Colozza, M., Larsimont, D., Piccart-Gebhart, M., Cardoso, F. (2008). HER-2 overexpression/amplification and its interaction with taxane-based therapy in breast cancer. Ann Oncol 19: 223-232 [Abstract] [Full Text]  
• Peoples, G. E., Holmes, J. P., Hueman, M. T., Mittendorf, E. A., Amin, A., Khoo, S., Dehqanzada, Z. A., Gurney, J. M., Woll, M. M., Ryan, G. B., Storrer, C. E., Craig, D., Ioannides, C. G., Ponniah, S. (2008). Combined Clinical Trial Results of a HER2/neu (E75) Vaccine for the Prevention of Recurrence in High-Risk Breast Cancer Patients: U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02. Clin. Cancer Res. 14: 797-803 [Abstract] [Full Text]  
• Sengupta, P. P., Northfelt, D. W., Gentile, F., Zamorano, J. L., Khandheria, B. K. (2008). Trastuzumab-Induced Cardiotoxicity: Heart Failure at the Crossroads. Mayo Clin Proc. 83: 197-203 [Abstract] [Full Text]  
• Wang, Y., Ikeda, D. M., Narasimhan, B., Longacre, T. A., Bleicher, R. J., Pal, S., Jackman, R. J., Jeffrey, S. S. (2008). Estrogen Receptor-Negative Invasive Breast Cancer: Imaging Features of Tumors with and without Human Epidermal Growth Factor Receptor Type 2 Overexpression. Radiology 246: 367-375 [Abstract] [Full Text]  
• Revillion, F., Lhotellier, V., Hornez, L., Bonneterre, J., Peyrat, J.-P. (2008). ErbB/HER ligands in human breast cancer, and relationships with their receptors, the bio-pathological features and prognosis. Ann Oncol 19: 73-80 [Abstract] [Full Text]  
• Bird, B. R.J. H., Swain, S. M. (2008). Cardiac Toxicity in Breast Cancer Survivors: Review of Potential Cardiac Problems. Clin. Cancer Res. 14: 14-24 [Abstract] [Full Text]  
• Wolff, A. C., Paik, S., Press, M. F. (2008). HER2 as a Predictive Marker: Why Bother Testing?. Am Soc Clin Oncol Ed Book 2008: 25-28 [Abstract] [Full Text]  
• Saad, A., Beto, R., Abraham, J., Remick, S. C. (2008). Cardiovascular Safety and Toxicity Profile of New Molecularly Targeted Anticancer Agents. Am Soc Clin Oncol Ed Book 2008: 428-434 [Abstract] [Full Text]  
• Sapino, A., Montemurro, F., Marchio, C., Viale, G., Kulka, J., Donadio, M., Bottini, A., Botti, G., dei Tos, A. P., Bersiga, A., Di Palma, S., Truini, M., Sanna, G., Aglietta, M., Bussolati, G. (2007). Patients with advanced stage breast carcinoma immunoreactive to biotinylated Herceptin(R) are most likely to benefit from trastuzumab-based therapy: an hypothesis-generating study. Ann Oncol 18: 1963-1968 [Abstract] [Full Text]  
• Widakowich, C., de Castro, G. Jr., de Azambuja, E., Dinh, P., Awada, A. (2007). Review: Side Effects of Approved Molecular Targeted Therapies in Solid Cancers. The Oncologist 12: 1443-1455 [Abstract] [Full Text]  
• Harris, L., Fritsche, H., Mennel, R., Norton, L., Ravdin, P., Taube, S., Somerfield, M. R., Hayes, D. F., Bast, R. C. Jr (2007). American Society of Clinical Oncology 2007 Update of Recommendations for the Use of Tumor Markers in Breast Cancer. JCO 25: 5287-5312 [Abstract] [Full Text]  
• Arnould, L., Arveux, P., Couturier, J., Gelly-Marty, M., Loustalot, C., Ettore, F., Sagan, C., Antoine, M., Penault-Llorca, F., Vasseur, B., Fumoleau, P., Coudert, B. P. (2007). Pathologic Complete Response to Trastuzumab-Based Neoadjuvant Therapy Is Related to the Level of HER-2 Amplification. Clin. Cancer Res. 13: 6404-6409 [Abstract] [Full Text]  
• Winer, E. P., Harris, J. R., Smith, B. L., D'Alessandro, H. A., Brachtel, E. F. (2007). Case 32-2007 -- A 62-Year-Old Woman with a Second Breast Cancer. NEJM 357: 1640-1648 [Full Text]  
• Hayes, D. F., Thor, A. D., Dressler, L. G., Weaver, D., Edgerton, S., Cowan, D., Broadwater, G., Goldstein, L. J., Martino, S., Ingle, J. N., Henderson, I. C., Norton, L., Winer, E. P., Hudis, C. A., Ellis, M. J., Berry, D. A., the Cancer and Leukemia Group B (CALGB) Investiga, (2007). HER2 and Response to Paclitaxel in Node-Positive Breast Cancer. NEJM 357: 1496-1506 [Abstract] [Full Text]  
• Bentzen, S. M., Trotti, A. (2007). Evaluation of Early and Late Toxicities in Chemoradiation Trials. JCO 25: 4096-4103 [Abstract] [Full Text]  
• Haines, I. E. (2007). A Positive Step Forward, but More Needed to Maximize Cost Benefits of New-Generation Cancer Therapies. JCO 25: e31-e32 [Full Text]  
• Dedes, K., Szucs, T., Imesch, P, Fedier, A, Fehr, M., Fink, D (2007). Cost-effectiveness of trastuzumab in the adjuvant treatment of early breast cancer: a model-based analysis of the HERA and FinHer trial. Ann Oncol 18: 1493-1499 [Abstract] [Full Text]  
• Carver, J. R., Shapiro, C. L., Ng, A., Jacobs, L., Schwartz, C., Virgo, K. S., Hagerty, K. L., Somerfield, M. R., Vaughn, D. J., for the ASCO Cancer Survivorship Expert Panel, (2007). American Society of Clinical Oncology Clinical Evidence Review on the Ongoing Care of Adult Cancer Survivors: Cardiac and Pulmonary Late Effects. JCO 25: 3991-4008 [Abstract] [Full Text]  
• Pearson, S.-A., Ringland, C. L., Ward, R. L. (2007). Trastuzumab and Metastatic Breast Cancer: Trastuzumab Use in Australia Monitoring the Effect of an Expensive Medicine Access Program. JCO 25: 3688-3693 [Abstract] [Full Text]  
• Ritter, C. A., Perez-Torres, M., Rinehart, C., Guix, M., Dugger, T., Engelman, J. A., Arteaga, C. L. (2007). Human Breast Cancer Cells Selected for Resistance to Trastuzumab In vivo Overexpress Epidermal Growth Factor Receptor and ErbB Ligands and Remain Dependent on the ErbB Receptor Network. Clin. Cancer Res. 13: 4909-4919 [Abstract] [Full Text]  
• Telli, M. L., Hunt, S. A., Carlson, R. W., Guardino, A. E. (2007). Trastuzumab-Related Cardiotoxicity: Calling Into Question the Concept of Reversibility. JCO 25: 3525-3533 [Abstract] [Full Text]  
• Hudis, C. A. (2007). Trastuzumab -- Mechanism of Action and Use in Clinical Practice. NEJM 357: 39-51 [Full Text]  
• Goldhirsch, A., Wood, W. C., Gelber, R. D., Coates, A. S., Thurlimann, B., Senn, H. -J., Panel Members, (2007). Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Ann Oncol 18: 1133-1144 [Abstract] [Full Text]  
• Coudert, B. P., Largillier, R., Arnould, L., Chollet, P., Campone, M., Coeffic, D., Priou, F., Gligorov, J., Martin, X., Trillet-Lenoir, V., Weber, B., Bleuse, J. P., Vasseur, B., Serin, D., Namer, M. (2007). Multicenter Phase II Trial of Neoadjuvant Therapy With Trastuzumab, Docetaxel, and Carboplatin for Human Epidermal Growth Factor Receptor-2 Overexpressing Stage II or III Breast Cancer: Results of the GETN(A)-1 Trial. JCO 25: 2678-2684 [Abstract] [Full Text]  
• Singh, S., Shi, Q., Bailey, S. T., Palczewski, M. J., Pardee, A. B., Iglehart, J. D., Biswas, D. K. (2007). Nuclear factor-{kappa}B activation: a molecular therapeutic target for estrogen receptor-negative and epidermal growth factor receptor family receptor-positive human breast cancer. Molecular Cancer Therapeutics 6: 1973-1982 [Abstract] [Full Text]  
• Barok, M., Isola, J., Palyi-Krekk, Z., Nagy, P., Juhasz, I., Vereb, G., Kauraniemi, P., Kapanen, A., Tanner, M., Vereb, G., Szollosi, J. (2007). Trastuzumab causes antibody-dependent cellular cytotoxicity-mediated growth inhibition of submacroscopic JIMT-1 breast cancer xenografts despite intrinsic drug resistance. Molecular Cancer Therapeutics 6: 2065-2072 [Abstract] [Full Text]  
• Chan, A (2007). A review of the use of trastuzumab (Herceptin(R)) plus vinorelbine in metastatic breast cancer. Ann Oncol 18: 1152-1158 [Abstract] [Full Text]  
• Wells, J., Cheong-Leen, C. (2007). NICE appraisals should be everybody's business. BMJ 334: 936-938 [Full Text]  
• Di Leo, A (2007). The state of HER-2 status. Ann Oncol 18: 813-815 [Full Text]  
• Simon, R. (2007). New challenges for 21st century clinical trials. Clin Trials 4: 167-169  
• Lin, N. U., Winer, E. P. (2007). Brain Metastases: The HER2 Paradigm. Clin. Cancer Res. 13: 1648-1655 [Abstract] [Full Text]  
• Jordan, V. C. (2007). SERMs: Meeting the Promise of Multifunctional Medicines. JNCI J Natl Cancer Inst 99: 350-356 [Abstract] [Full Text]  
• Hillner, B. E., Smith, T. J. (2007). Do the Large Benefits Justify the Large Costs of Adjuvant Breast Cancer Trastuzumab?. JCO 25: 611-613 [Full Text]  
• Kurian, A. W., Thompson, R. N., Gaw, A. F., Arai, S., Ortiz, R., Garber, A. M. (2007). A Cost-Effectiveness Analysis of Adjuvant Trastuzumab Regimens in Early HER2/neu-Positive Breast Cancer. JCO 25: 634-641 [Abstract] [Full Text]  
• Arteaga, C. L. (2007). Will Single-Time Tumor Profiling and a "Guilt by Association" Approach Allow Us to Outsmart HER2-Positive Breast Cancer?. Clin. Cancer Res. 13: 1071-1073 [Full Text]  
• Toledano, A., Azria, D., Garaud, P., Fourquet, A., Serin, D., Bosset, J.-F., Miny-Buffet, J., Favre, A., Le Floch, O., Calais, G. (2007). Phase III Trial of Concurrent or Sequential Adjuvant Chemoradiotherapy After Conservative Surgery for Early-Stage Breast Cancer: Final Results of the ARCOSEIN Trial. JCO 25: 405-410 [Abstract] [Full Text]  
• Shimizu, C., Ando, M., Kouno, T., Katsumata, N., Fujiwara, Y. (2007). Current Trends and Controversies over Pre-operative Chemotherapy for Women with Operable Breast Cancer. Jpn J Clin Oncol 0: hyl122v1-8 [Abstract] [Full Text]  
• Ozols, R. F., Herbst, R. S., Colson, Y. L., Gralow, J., Bonner, J., Curran, W. J. Jr, Eisenberg, B. L., Ganz, P. A., Kramer, B. S., Kris, M. G., Markman, M., Mayer, R. J., Raghavan, D., Reaman, G. H., Sawaya, R., Schilsky, R. L., Schuchter, L. M., Sweetenham, J. W., Vahdat, L. T., Winn, R. J. (2007). Clinical Cancer Advances 2006: Major Research Advances in Cancer Treatment, Prevention, and Screening--A Report From the American Society of Clinical Oncology. JCO 25: 146-162 [Abstract] [Full Text]  
• Wolff, A. C., Hammond, M. E. H., Schwartz, J. N., Hagerty, K. L., Allred, D. C., Cote, R. J., Dowsett, M., Fitzgibbons, P. L., Hanna, W. M., Langer, A., McShane, L. M., Paik, S., Pegram, M. D., Perez, E. A., Press, M. F., Rhodes, A., Sturgeon, C., Taube, S. E., Tubbs, R., Vance, G. H., van de Vijver, M., Wheeler, T. M., Hayes, D. F. (2007). American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer. JCO 25: 118-145 [Abstract] [Full Text]  
• Chang, J. C. (2007). HER2 Inhibition: From Discovery to Clinical Practice. Clin. Cancer Res. 13: 1-3 [Full Text]  
• Buzdar, A. U., Valero, V., Ibrahim, N. K., Francis, D., Broglio, K. R., Theriault, R. L., Pusztai, L., Green, M. C., Singletary, S. E., Hunt, K. K., Sahin, A. A., Esteva, F., Symmans, W. F., Ewer, M. S., Buchholz, T. A., Hortobagyi, G. N. (2007). Neoadjuvant Therapy with Paclitaxel followed by 5-Fluorouracil, Epirubicin, and Cyclophosphamide Chemotherapy and Concurrent Trastuzumab in Human Epidermal Growth Factor Receptor 2-Positive Operable Breast Cancer: An Update of the Initial Randomized Study Population and Data of Additional Patients Treated with the Same Regimen. Clin. Cancer Res. 13: 228-233 [Abstract] [Full Text]  
• Goldhirsch, A, Coates, A., Gelber, R., Glick, J., Thurlimann, B, Senn, H-J, On behalf of the St Gallen Expert Panel Members, (2006). First--select the target: better choice of adjuvant treatments for breast cancer patients. Ann Oncol 17: 1772-1776 [Abstract] [Full Text]  
• Barrett, A., Roques, T., Small, M., Smith, R. D (2006). How much will Herceptin really cost?. BMJ 333: 1118-1120 [Full Text]  
• Meric-Bernstam, F., Hung, M.-C. (2006). Advances in targeting human epidermal growth factor receptor-2 signaling for cancer therapy.. Clin. Cancer Res. 12: 6326-6330 [Abstract] [Full Text]  
• Dal Lago, L., Durbecq, V., Desmedt, C., Salgado, R., Verjat, T., Lespagnard, L., Ma, Y., Veys, I., Di Leo, A., Sotiriou, C., Piccart, M., Larsimont, D. (2006). Correction for chromosome-17 is critical for the determination of true Her-2/neu gene amplification status in breast cancer.. Molecular Cancer Therapeutics 5: 2572-2579 [Abstract] [Full Text]  
• Hayes, D. F., Picard, M. H. (2006). Heart of Darkness: The Downside of Trastuzumab. JCO 24: 4056-4058 [Full Text]  
• Gonzalez-Angulo, A. M., Hortobagyi, G. N., Esteva, F. J. (2006). Adjuvant Therapy with Trastuzumab for HER-2/neu-Positive Breast Cancer. The Oncologist 11: 857-867 [Abstract] [Full Text]  
• Cameron, D., Bell, R., Aapro, M., Zielinski, C. (2006). What Are the Current Standards of Care and Recent Developments in the Management of Breast Cancer?. The Oncologist 11: 1-3 [Full Text]  
• Baselga, J., Perez, E. A., Pienkowski, T., Bell, R. (2006). Adjuvant Trastuzumab: A Milestone in the Treatment of HER-2-Positive Early Breast Cancer. The Oncologist 11: 4-12 [Abstract] [Full Text]  
• Ferretti, G., Papaldo, P., Fabi, A., Carlini, P., Felici, A., Cognetti, F. (2006). Adjuvant Trastuzumab with Docetaxel or Vinorelbine for HER-2-Positive Breast Cancer. The Oncologist 11: 853-854 [Full Text]  
• Sachelarie, I., Grossbard, M. L., Chadha, M., Feldman, S., Ghesani, M., Blum, R. H. (2006). Primary Systemic Therapy of Breast Cancer. The Oncologist 11: 574-589 [Abstract] [Full Text]  
• Montemurro, F., Valabrega, G., Aglietta, M., Joensuu, H., Bono, P., Kellokumpu-Lehtinen, P. (2006). Trastuzumab Treatment in Breast Cancer. NEJM 354: 2186-2186 [Full Text]  
• (2006). More About Adjuvant Trastuzumab for Breast Cancer. JWatch General 2006: 3-3 [Full Text]